glp 1 non alcoholic fatty liver Why are GLP-1 agonists being used to treat patients with nonalcoholic disease? Current Status of Glucagon-like Peptide-1

These results are unprecedented in the field of obesity medicine, rivaling the outcomes of some bariatric surgeries

In an analysis of two large health care utilization cohorts SGLT2 inhibitors were not associated with an increased risk of acute kidney injury (219)

doi: 10.1016/S0140-6736(18)32261-X 42 GersteinHCColhounHMDagenaisGRDiazRLakshmananMPaisPet al

Overall intestinal absorption rate of allulose has been estimated to be approximately 70 % of oral dose (Reference Tsukamoto, Hossain and Yamaguchi14,Reference Moura15)

Semaglutide is a once-weekly injectable medication that has shown significant weight loss benefits in clinical trials